Patents by Inventor Duxin Sun
Duxin Sun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230404427Abstract: A method is presented for tracking an ingestible device in a gastrointestinal tract of a subject. The method includes: measuring acceleration of the ingestible device as it traverses through the gastrointestinal tract, for example using an accelerometer disposed in the ingestible device; computing a metric from the acceleration measurements obtained by the accelerometer over a given period of time; and identifying a location in the gastrointestinal tract based in part on the metric.Type: ApplicationFiled: June 16, 2023Publication date: December 21, 2023Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Duxin SUN, Yogesh GIANCHANDANI, Tao LI, Jeremy FELTON, Hsueh-Tsung LU, Alexander BENKEN, Partha DUTTA, Xiangyu ZHAO, Manjunath PAI
-
Patent number: 11701433Abstract: The present invention provides methods, compositions, systems, and kits comprising nano-satellite complexes and/or serum albumin carrier complexes, which are used for modulating antigen-specific immune response (e.g., enhancing anti-tumor immunity). In certain embodiments, the nano-satellite complexes comprise: a) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; b) at least one satellite particle attached to, or absorbed to, the biocompatible coating; and c) an antigenic component conjugated to, or absorbed to, the at least one satellite particle component. In certain embodiments, the complexes further comprise: d) an type I interferon agonist agent. In some embodiments, the serum albumin complexes comprise: a) at least part of a serum albumin protein, b) an antigenic component conjugated to the carrier protein, and c) a type I interferon agonist agent.Type: GrantFiled: June 1, 2018Date of Patent: July 18, 2023Assignee: The Regents of the University of MichiganInventors: Yu Lei, Yee Sun Tan, Kanokwan Sansanaphongpricha, Duxin Sun, Hongwei Chen, Hongxiang Hu
-
Publication number: 20230183282Abstract: The present invention relates to methods, compounds, and compositions for treating viral infections, including COVID-19 viral infections. In certain embodiments, the compositions comprise: i) a remdesivir analog, ii) remdesivir or a remdesivir analog, and a surfactant, a cyclodextrin, or a combination thereof, iii) nanoparticles comprising albumin and remdesivir or remdesivir analog, iv) liposomes comprising lipids and remdesivir or remdesivir analog; and/or v) microparticles comprising PLA and/or PLGA, and remdesivir or remdesivir analog. In certain embodiments, the compositions are aqueous (e.g., for intravenous administration). In other embodiments, the compositions are nebulized or in the form of a dry powder (e.g., for inhalation by an infected subject).Type: ApplicationFiled: April 1, 2021Publication date: June 15, 2023Inventors: Duxin Sun, Wei Gao, Hongxiang Hu, Mohamed Dit Mady Traore, Yudong Song, Bo Wen, Miao He, Hebao Yuan, Ruiting Li
-
Patent number: 11647959Abstract: An ingestible electronic capsule for the collection of samples along a gastric intestinal tract and methods relating thereto are provided. The ingestible electronic capsule includes a housing and a cap that form an interior chamber. The cap includes a sampling port and one or more sample collection chambers are disposed within the interior chamber. A motor is also disposed within the interior chamber and is configured to rotate one of the cap and the one or more sample collection chambers so to align one or the one or more sample collection chambers and the sampling port of the cap so to allow for sample collection. A microcontroller is also disposed within the interior chamber and is in communication with at least the motor. The microcontroller is configured to control the selective alignment of the sampling port and one of the one or more sample collection chambers and induce gastric intestinal fluid sampling.Type: GrantFiled: January 2, 2019Date of Patent: May 16, 2023Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Duxin Sun, Yogesh B. Gianchandani, Tao Li, Jinhui Liao, Qisen Cheng, Johnathan Lewis, Ryan Meredith, Jeremy Felton
-
Publication number: 20230025865Abstract: This disclosure provides compositions and methods for albumin nanoformulation of Bcl-2 and Bcl-xL inhibitor APG-1252 to suppress and/or inhibit growth of cancer cells (e.g., tumor cells). In particular, the present invention is directed to compositions comprising nanoparticles associated with (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, admixed) APG-1252, methods for synthesizing such nanoparticles, as well as systems and methods utilizing such nanoparticles (e.g., in diagnostic and/or therapeutic settings). Such nanoparticle formulations of APG-1252 are capable of increasing solubility, protecting against its degradation, reducing platelet toxicity, and expanding (improving) different indications to improve anticancer efficacy in various cancers and cancer metastasis in lymph nodes.Type: ApplicationFiled: December 11, 2020Publication date: January 26, 2023Inventors: Duxin Sun, Wei Gao, Hongxiang Hu
-
Publication number: 20210346478Abstract: The present invention provides, in some embodiments, methods, compositions, systems, and kits comprising nano-satellite complexes comprising: a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; 3-25 satellite particles attached to, or absorbed to, said biocompatible coating; a plurality of antigenic peptides conjugated to, or absorbed to, said satellite particles; and at least one additional property. In other embodiments, provided herein are nano-satellite complexes comprising: a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; a plurality of satellite particles attached to, or absorbed to, said biocompatible coating; a plurality of antigenic peptides conjugated to, or absorbed to, said satellite particles; and a plurality of LIGHT (TNFSF14) peptides conjugated to, or absorbed to, said satellite particles.Type: ApplicationFiled: April 16, 2021Publication date: November 11, 2021Inventors: Duxin Sun, Ryan Clauson, Hongwei Chen, Chengyi Li, Wei Gao, Luke Bugada, Fei Wen, Brett Hill, Syed Monem Rizvi
-
Patent number: 10898595Abstract: The present invention provides methods, compositions, systems, and kits comprising core-satellite nanocomposites useful for photothermal and/or MRI applications (e.g., tumor treatment and/or imaging). In certain embodiments, the core-satellite nanocomposites comprise: i) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core, and ii) at least one satellite component attached to, or absorbed to, the biocompatible coating. In some embodiments, the nanoparticle core and satellite component are composed of near-infrared photothermal agent material and/or MRI contrast agent material. In further embodiments, the satellite component is additionally or alternatively composed of near-infrared optical dye material.Type: GrantFiled: November 25, 2019Date of Patent: January 26, 2021Assignee: The Regents of the University of MichiganInventors: Hongwei Chen, Duxin Sun
-
Publication number: 20200367828Abstract: An ingestible electronic capsule for the collection of samples along a gastric intestinal tract and methods relating thereto are provided. The ingestible electronic capsule includes a housing and a cap that form an interior chamber. The cap includes a sampling port and one or more sample collection chambers are disposed within the interior chamber. A motor is also disposed within the interior chamber and is configured to rotate one of the cap and the one or more sample collection chambers so to align one or the one or more sample collection chambers and the sampling port of the cap so to allow for sample collection. A microcontroller is also disposed within the interior chamber and is in communication with at least the motor. The microcontroller is configured to control the selective alignment of the sampling port and one of the one or more sample collection chambers and induce gastric intestinal fluid sampling.Type: ApplicationFiled: January 2, 2019Publication date: November 26, 2020Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Duxin SUN, Yogesh B. GIANCHANDANI, Tao LI, Jinhui LIAO, Qisen CHENG, Johnathan LEWIS, Ryan MEREDITH, Jeremy FELTON
-
Publication number: 20200164094Abstract: The present invention provides methods, compositions, systems, and kits comprising core-satellite nanocomposites useful for photothermal and/or MRI applications (e.g., tumor treatment and/or imaging). In certain embodiments, the core-satellite nanocomposites comprise: i) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core, and ii) at least one satellite component attached to, or absorbed to, the biocompatible coating. In some embodiments, the nanoparticle core and satellite component are composed of near-infrared photothermal agent material and/or MRI contrast agent material. In further embodiments, the satellite component is additionally or alternatively composed of near-infrared optical dye material.Type: ApplicationFiled: November 25, 2019Publication date: May 28, 2020Inventors: Hongwei Chen, Duxin Sun
-
Publication number: 20200129640Abstract: The present invention provides methods, compositions, systems, and kits comprising nano-satellite complexes and/or serum albumin carrier complexes, which are used for modulating antigen-specific immune response (e.g., enhancing anti-tumor immunity). In certain embodiments, the nano-satellite complexes comprise: a) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; b) at least one satellite particle attached to, or absorbed to, the biocompatible coating; and c) an antigenic component conjugated to, or absorbed to, the at least one satellite particle component. In certain embodiments, the complexes further comprise: d) an type I interferon agonist agent. In some embodiments, the serum albumin complexes comprise: a) at least part of a serum albumin protein, b) an antigenic component conjugated to the carrier protein, and c) a type I interferon agonist agent.Type: ApplicationFiled: June 1, 2018Publication date: April 30, 2020Inventors: Yu Lei, Yee Sun Tan, Kanokwan Sansanaphongpricha, Duxin Sun, Hongwei Chen, Hongxiang Hu
-
Patent number: 10485886Abstract: The present invention provides methods, compositions, systems, and kits comprising core-satellite nanocomposites useful for photothermal and/or MRI applications (e.g., tumor treatment and/or imaging). In certain embodiments, the core-satellite nanocomposites comprise: i) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core, and ii) at least one satellite component attached to, or absorbed to, the biocompatible coating. In some embodiments, the nanoparticle core and satellite component are composed of near-infrared photothermal agent material and/or MRI contrast agent material. In further embodiments, the satellite component is additionally or alternatively composed of near-infrared optical dye material.Type: GrantFiled: May 7, 2018Date of Patent: November 26, 2019Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Hongwei Chen, Duxin Sun
-
Patent number: 10391175Abstract: Inhibitors of BET bromodomains and compositions containing the same are disclosed. Methods of using the BET bromodomain inhibitors in the treatment of diseases and conditions wherein inhibition of BET bromodomain provides a benefit, like cancers, also are disclosed.Type: GrantFiled: June 12, 2017Date of Patent: August 27, 2019Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Shaomeng Wang, Xu Ran, Yujun Zhao, Chao-Yie Yang, Liu Liu, Longchuan Bai, Donna McEachern, Jeanne Stuckey, Jennifer Lynn Meagher, Duxin Sun, Xiaoqin Li, Bing Zhou, Hacer Karatas, Ruijuan Luo, Arul Chinnaiyan, Irfan A. Asangani
-
Patent number: 10253044Abstract: The present disclosure provides substituted 9H-pyrimido[4,5-b]indoles and 5H-pyrido[4,3-b]indoles and related analogs represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1a, A, B1, B2, G, X1, Y1, Y2, and Y3 are as defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a condition or disorder responsive to inhibition of BET bromodomains. Compounds of the present disclosure are especially useful for treating cancer.Type: GrantFiled: February 27, 2017Date of Patent: April 9, 2019Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Shaomeng Wang, Yujun Zhao, Bing Zhou, Angelo Aguilar, Liu Liu, Longchuan Bai, Donna McEachern, Duxin Sun, Bo Wen, Ruijuan Luo, Ting Zhao, Arul Chinnaiyan, Irfan A. Asangani, Jeanne Stuckey, Jennifer Lynn Meagher, Xu Ran, Yang Hu
-
Patent number: 10246464Abstract: The present disclosure provides compounds and methods for inhibiting the interaction of menin with its upstream or downstream signaling molecules including but not limited to MLL1, MLL2 and MLL-fusion oncoproteins. Compounds of the disclosure may be used in methods for the treatment of a wide variety of cancers and other diseases associated with one or more of MLL1, MLL2, MLL fusion proteins, and menin.Type: GrantFiled: September 8, 2015Date of Patent: April 2, 2019Assignees: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, KURA ONCOLOGY, INC.Inventors: Jolanta Grembecka, Tomasz Cierpicki, Dmitry Borkin, Jonathan Pollock, Hongzhi Miao, Duxin Sun, Liansheng Li, Tao Wu, Jun Feng, Pingda Ren, Yi Liu
-
Patent number: 10202340Abstract: Glucosylceramide synthase inhibitors and compositions containing the same are disclosed. Methods of using the glucosylceramide synthase inhibitors in the treatment of diseases and conditions wherein inhibition of glucosylceramide synthase provides a benefit, like Gaucher disease and Fabry disease, also are disclosed.Type: GrantFiled: February 1, 2016Date of Patent: February 12, 2019Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Scott D. Larsen, Akira Abe, Liming Shu, Michael William Wilson, Richard F. Keep, Duxin Sun, James A. Shayman
-
Patent number: 10160769Abstract: The present disclosure relates generally to thienopyrimidine and thienopyridine compounds and methods of use thereof. In particular embodiments, the present disclosure provides compositions comprising thienopyrimidine and thienopyridine compounds of Formula 3: and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins.Type: GrantFiled: October 18, 2016Date of Patent: December 25, 2018Assignee: The Regents of the University of MichiganInventors: Jolanta Grembecka, Tomasz Cierpicki, Dmitry Borkin, Jay L. Hess, Duxin Sun, Xiaoqin Li, Kevin Greenman, Mohamed Ibrahim, Artem Plekhov
-
Publication number: 20180256757Abstract: The present invention provides methods, compositions, systems, and kits comprising core-satellite nanocomposites useful for photothermal and/or MRI applications (e.g., tumor treatment and/or imaging). In certain embodiments, the core-satellite nanocomposites comprise: i) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core, and ii) at least one satellite component attached to, or absorbed to, the biocompatible coating. In some embodiments, the nanoparticle core and satellite component are composed of near-infrared photothermal agent material and/or MRI contrast agent material. In further embodiments, the satellite component is additionally or alternatively composed of near-infrared optical dye material.Type: ApplicationFiled: May 7, 2018Publication date: September 13, 2018Inventors: Hongwei Chen, Duxin Sun
-
Publication number: 20180140550Abstract: The present invention provides compositions, systems, and methods employing cleavable polymeric micelles. For example, provided herein are compositions comprising micelles that contain a hydrophobic agent (e.g., metal nanoparticles and/or therapeutic agent), where the micelles are formed from a plurality of amphiphilic polymer molecules that comprise a hydrophilic polymer and a hydrophobic polymer, where the hydrophobic polymer comprises a cleavable Furan-Maleimide adduct. Also provided herein are methods of administering such compositions to a subject and treating a localized area of the subject with a device that emits heat, NIR light, and/or alternating magnetic current such that at least some of the micelles inside the subject near the localized area are disrupted (e.g., releasing a therapeutic agent).Type: ApplicationFiled: January 17, 2018Publication date: May 24, 2018Inventors: Kanokwan Sansanaphongpricha, Hongwei Chen, Duxin Sun
-
Publication number: 20180125432Abstract: Differences of electromagnetic (EM) properties between healthy and cancerous tissues allow detection of abnormal conditions occurring in a tissue of an animal, for example, intra-operative cancer detection. By using a time-varying EM field, electrical eddy currents are generated in the tissue sample, and assessed using phase-sensitive detection. In some aspects, a change in phase shift between the voltage in a receiver coil and the voltage in a driver coil provide a direct and immediate indication of differences in EM properties of specimens.Type: ApplicationFiled: December 18, 2017Publication date: May 10, 2018Inventors: Vishwanath Subramaniam, Joseph West, Jennifer McFerran Brock, Emily Sequin, Duxin Sun, Peng Zou, Travis Hamilton Jones
-
Patent number: RE49687Abstract: The present disclosure provides compounds and methods for inhibiting the interaction of menin with its upstream or downstream signaling molecules including but not limited to MLL1, MLL2 and MLL-fusion oncoproteins. Compounds of the disclosure may be used in methods for the treatment of a wide variety of cancers and other diseases associated with one or more of MLL1, MLL2, MLL fusion proteins, and menin.Type: GrantFiled: February 2, 2021Date of Patent: October 10, 2023Assignees: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, KURA ONCOLOGY, INC.Inventors: Jolanta Grembecka, Tomasz Cierpicki, Dmitry Borkin, Jonathan Pollock, Hongzhi Miao, Duxin Sun, Liansheng Li, Tao Wu, Jun Feng, Pingda Ren, Yi Liu